Explore / Clinical trial
Clinical trial

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

University of California, San DiegoCompletedPhase 2Started May 1, 202116 enrolledUnited StatesNCT04661514

Abstract

The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinEating disorders

Keywords

AnorexiaAnorexia Nervosa Signs and SymptomsMental DisordersHallucinogensPhysiological Effects of DrugsPsychotropic DrugsPsychedelic DrugsAnorexia Nervosa

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.